This program offers a unique opportunity for businesses involved in research and technology development related to brain imaging. By applying, you can gain access to grant funding for preclinical studies and model development. This is an excellent way to support your projects, covering essential research costs and maximizing your potential for breakthroughs in drug discovery.

There are no constraints on employee count or revenue, making it inclusive and accessible for any business. Engaging with this program can position your company as a leader in developing novel radioligands for PET and SPECT imaging. Such advancements have the potential to enhance understanding of neurological disorders, ultimately benefiting patient outcomes and advancing your business in the medical research field.

Taking part in this program can accelerate your innovation efforts and shine a spotlight on your capabilities. With funding available nationwide, you’ll have the chance to collaborate with other experts and contribute to groundbreaking developments in brain health. Don't miss out on this pivotal step toward growing your business and expanding your research horizons.

This program offers a grant for the development of novel radioligands. Unlike loans, grants do not require repayment, which means more funds remain available for your project's growth.

Eligible Expenses:

• The funding can be used for the preclinical development of radioligands specifically for positron emission tomography (PET) or single photon emission computed tomography (SPECT).
• This includes costs related to pilot or clinical feasibility evaluation and model development.

Restrictions:

• The funds cannot be used for projects simply proposing clinical assessments of novel radioligands; those should pursue a different funding opportunity.
• There are no specific fees associated with this funding opportunity, but ensure that your expense claims align with the stipulated eligible uses to avoid any issues during the review process.

This grant represents a strong opportunity to advance your research without the burden of repayment.

• Location: Available nationally across the country.
• Sectors: Open to all sectors.
• Legal Structure: All legal structures are applicable.
• Profit Structure: All profit structures qualify.
• Minimum Employees: No minimum employees required.
• Maximum Employees: No maximum employees required.
• Minimum Company Revenue: No minimum revenue qualifications.
• Maximum Company Revenue: No maximum revenue qualifications.

Disqualifications:

• Program Type: Funding is only available for research applications focused on preclinical development of novel radioligands for PET or SPECT imaging.

This program supports the development of new imaging technologies for studying brain conditions. If you're involved in research or technology development, this funding can help you create novel radioligands for PET or SPECT imaging. These advancements can enhance your ability to discover new drugs or understand neurological disorders better.

You'll find grant funding available to assist with preclinical studies and model development. Although specific amounts aren't detailed, the funding can help cover necessary research costs. This support can be crucial for advancing your projects and potentially improving patient outcomes.

The funds are available nationwide, giving your business the chance to collaborate and innovate. Utilizing this opportunity can put you at the forefront of medical research, enabling you to contribute significantly to drug discovery and the understanding of brain diseases.